Thermo Fisher Scientific
TMO
683.70
+4.32
+0.64%
Thermo Fisher Scientific
US · TMO
#80 by market cap
Listed 1970
683.70
+4.32
+0.64%
Live - 5344 symbols - heartbeat 18s ago
· 2026-10-20 11:00
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 25 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.2 percentage points.
Institutional ownership
- Held by institutions
- 92.83% -0.16pp
- Institutions
- 3,108 -25
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund75.50%
Public Company5.62%
Hedge Fund3.91%
Government Pension Fund2.05%
Private Company2.00%
Sovereign Wealth Fund1.46%
VC/PE Fund1.00%
Family Office/Trust0.55%
Corporate Pension Plan0.31%
Other7.62%
Top holders as of 2026-06-30
BlackRock
8.36% · 30.92M sh
Vanguard Capital Management, LLC
7.13% · 26.36M sh
State Street Global Advisors
4.55% · 16.83M sh
Capital Research
3.71% · 13.73M sh
FMR
3.32% · 12.26M sh
Other
72.93%
Geode Capital Management, LLC
2.27% · 8.38M sh
Morgan Stanley
1.78% · 6.57M sh
Vanguard Portfolio Management, LLC
1.68% · 6.23M sh
T. Rowe Price Group, Inc.
1.39% · 5.13M sh
Norges Bank Investment Management
1.38% · 5.09M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 22 buys · 28 sells
| Name | Role | Stake |
|---|---|---|
| Marc Casper | Chairperson & CEO | 0.03% |
| Michel Lagarde | Chief Operating Officer | 0.02% |
| Scott Sperling | Lead Independent Director | 0.02% |
| Stephen Williamson | Senior Vice President | 0.01% |
| Gianluca Pettiti | Executive Vice President | 0.01% |
| Michael Shafer | Senior VP & President of Pharma Services Group | 0.00% |
| Nelson Chai | Independent Director | 0.00% |
| Frederick Lowery | Senior VP & President of Customer Channels | 0.00% |
| Lisa Britt | Chief Human Resources Officer & Senior VP | 0.00% |
| Michael Boxer | General Counsel | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-25 | Scott Sperling | Lead Independent Director | Other Derivative Acquisition | +62 | -- |
| 2026-09-25 | Jennifer Johnson | Independent Director | Other Derivative Acquisition | +46 | -- |
| 2026-09-25 | Karen Lynch | Independent Director | Other Derivative Acquisition | +46 | -- |
| 2026-09-25 | Dion Weisler | Independent Director | Other Derivative Acquisition | +55 | -- |
| 2026-09-25 | R. Keith | Independent Director | Other Derivative Acquisition | +46 | -- |
| 2026-08-30 | Gianluca Pettiti | President, COO & President of Products and Technologies | Automatic Disposition | -400 | $614.38 |
| 2026-08-30 | Gianluca Pettiti | President, COO & President of Products and Technologies | Derivative Exercise and Sale | -3,733 | $309.63–614.38 |
| 2026-08-27 | Marc Casper | Chairperson & CEO | Sale to Issuer | -1,256 | $622.18 |
| 2026-08-27 | Thomas Shropshire | Senior VP and General Counsel | Sale to Issuer | -49 | $622.18 |
| 2026-08-27 | Lisa Britt | Chief Human Resources Officer & Senior VP | Sale to Issuer | -393 | $622.18 |
| 2026-08-27 | Gianluca Pettiti | President, COO & President of Products and Technologies | Sale to Issuer | -1,034 | $622.18 |
| 2026-08-27 | Michael Shafer | Executive VP & President of Biopharma Services | Sale to Issuer | -790 | $622.18 |
| 2026-08-27 | Joseph Holmes | Vice President | Sale to Issuer | -49 | $622.18 |
| 2026-08-27 | James Meyer | Senior Vice President | Sale to Issuer | -270 | $622.18 |
| 2026-08-23 | Marc Casper | Chairperson & CEO | Derivative Exercise and Sale | -275 | $309.63–628.74 |
| 2026-08-21 | James Meyer | Senior Vice President | Sale to Issuer | -30 | $629.27 |
| 2026-08-20 | Marc Casper | Chairperson & CEO | Derivative Exercise and Sale | -20,000 | $309.63–633.99 |
| 2026-08-20 | Marc Casper | Chairperson & CEO | Intent to Sell (Form 144) | -10,000 | $626.91 |
| 2026-08-19 | Marc Casper | Chairperson & CEO | Intent to Sell (Form 144) | -10,000 | $629.27 |
| 2026-08-18 | Lisa Britt | Chief Human Resources Officer & Senior VP | Derivative Exercise and Sale | -11,440 | $418.32–613.12 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-20 11:00:13 · For reference only, not investment advice and not tailored to your situation.
Thermo Fisher Scientific discussion 0 comments